Romanian Society of Pharmaceutical Sciences
 

« Back to Farmacia Journal 6/2025

SYNTHESIS, CHARACTERISATION AND A PRELIMINARY IN VITRO EVALUATION OF A MAGNETIC NANOFORMULATION ON KIDNEY VERO CELL LINE

MIHAI CRISTIAN NEAGU 1,2, EUGEN SORIN BOIA 1, PAULA ALEXANDRA ANDRICĂ 2*, ANDREEA MARIA CRISTEA 3,4, DANIELA SASCO 3, FLAVIUS BOB 1,5,6, ANDREEA SMEU 3,4 , ALINA ANTON 3,4, ELENA-ALINA MOACĂ 3,4

1 Faculty of Medicine, “Victor Babeș” University of Medicine and Pharmacy Timișoara, 2nd Eftimie Murgu Square, 300041 Timișoara, Romania
2 Doctoral School of Medicine, “Victor Babeș” University of Medicine and Pharmacy Timișoara, 2nd Eftimie Murgu Square, 300041 Timișoara, Romania
3 Faculty of Pharmacy, “Victor Babeș” University of Medicine and Pharmacy Timișoara, 2nd Eftimie Murgu Square, 300041 Timișoara, Romania
4 Research Centre for Pharmaco-Toxicological Evaluations, “Victor Babeș” University of Medicine and Pharmacy Timișoara, 2nd Eftimie Murgu Square, 300041 Timișoara, Romania
5 Centre for Molecular Research in Nephrology and Vascular Disease, “Victor Babeș” University of Medicine and Pharmacy, 2nd Eftimie Murgu Square, 300041 Timișoara, Romania
6 County Emergency Hospital, 156 L. Rebreanu Street, 300723 Timișoara, Romania

Download Full Article PDF

The present study aimed to synthesise, characterise and evaluate in vitro a magnetic colloidal suspension (MCS) based on magnetic iron oxide nanoparticles (MIONPs) obtained by the combustion method and double-coated with vegetable oleic acid (OA), dispersed in aqueous media. Physical-chemical investigations showed that the synthesised sample (MCS_OA) has a hydrodynamic diameter (Dh) of 43.13 nm, a polydispersity index (PDI) of 0.524, a saturation magnetisation (Ms) of 1.06 Gs and an average particle size of 18.1 ± 2.1 nm with a narrow distribution of nanoparticle sizes determined by transmission electron microscopy (TEM). Preliminary in vitro analyses were performed after 24 hours of exposure on the Vero kidney cells. The results indicated that MCS_OA induces a dose-dependent decrease in cell viability, especially at a 2 μg/mL concentration, which was also confirmed by morphological changes in cells and by nuclear and mitochondrial dysmorphologies. Collectively, MCS_OA warrants additional research into its therapeutic potential, although further investigation is needed to ensure safety and efficacy in clinical applications.